MARKET

STSA

STSA

SATSUMA PHARMACEUTICALS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.680
+0.140
+3.08%
After Hours: 4.760 +0.08 +1.71% 16:49 11/27 EST
OPEN
4.600
PREV CLOSE
4.540
HIGH
4.860
LOW
4.540
VOLUME
353.74K
TURNOVER
--
52 WEEK HIGH
36.11
52 WEEK LOW
3.500
MARKET CAP
81.54M
P/E (TTM)
-1.7742
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the Evercore ISI 3rd Annual HealthCONx Conference. Please see additional details below:Dates:Tuesday – Thursday, December 1st-3rd 2020 Format:One-on-one meetings with Satsuma Management Location:Virtual Meetings About Satsuma Pharmaceuticals and STS101 Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product candidate for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients. However, broad use has been limited by invasive and burdensome administration and/or sub-optimal clinical performance of available injectable and liquid nasal spray products. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming these shortcomings.Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.INVESTOR AND CORPORATE CONTACTS:Corey Davis, PhD LifeSci Advisors, LLC cdavis@lifesciadvisors.comTom O’Neil, Chief Financial Officer Satsuma Pharmaceuticals, Inc. tom@satsumarx.com
GlobeNewswire · 4d ago
5 Value Stocks To Watch In The Healthcare Sector
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.The following stocks are considered to be notable value stocks in the healthcare sector: 1. Satsuma Pharmaceuticals (NASDAQ: STSA) - P/E: 2.34 2. Acorda Therapeutics (NASDAQ: ACOR) - P/E: 0.69 3. Biogen (NASDAQ: BIIB) - P/E: 8.05 4. Amneal Pharmaceuticals (NYSE: AMRX) - P/E: 9.13 5. Bio-Rad Laboratories (NYSE: BIO) - P/E: 4.88This quarter, Satsuma Pharmaceuticals experienced a decrease in earnings per share, which was -0.65 in Q2 and is now -0.69. Satsuma Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Acorda Therapeutics reported earnings per share at -0.23, whereas in Q2 earnings per share sat at -0.35. Acorda Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Biogen's earnings per share for Q3 sits at 8.84, whereas in Q2, they were at 10.26. Biogen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Amneal Pharmaceuticals reported earnings per share at 0.16, whereas in Q2 earnings per share sat at 0.13. Amneal Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.This quarter, Bio-Rad Laboratories experienced an increase in earnings per share, which was 1.61 in Q2 and is now 3.0. Bio-Rad Laboratories does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.See more from Benzinga * Click here for options trades from Benzinga * Overview Of Value Stocks In The Real Estate Sector * A Preview Of Dick's Sporting Goods's Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 5d ago
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 10/29 11:30
The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22)
Benzinga · 10/23 11:26
Satsuma Pharmaceuticals Enters Oversold Territory
Satsuma Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Zacks · 10/06 11:09
The Daily Biotech Pulse: Amag Spikes On Takeover Rumors, Zosano Wilts On Regulatory Setback, Pulmonx Makes Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30)
Benzinga · 10/01 12:18
The Daily Biotech Pulse: Eton Snags Second FDA Nod For Month, Vaccine Updates from Moderna, CureVac
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29)
Benzinga · 09/30 11:45
Satsuma: Not All Over For Migraine Treatment Despite Trial Failure
Satsuma shares have collapsed in value after the company's only drug candidate STS101 failed a late-stage trial in acute migraine treatment.The share price fell from $24, to $4, and most analysts have set a price target of $4.The EMERGE trial was not a complete blowout. STS101 - a DHE/nasal delivery combo showed statistical outperformance against placebo after a 3hr period and slight outperformance after 2hrs.It will take time, but I think the company can come back from this trial miss and has a few options on the table regarding winning approval.I think the share price may get worse before it gets better; however, I'd think about opening a position if it drops below $3, with a long-term price target of ~$10.
Seekingalpha · 09/25 22:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of STSA. Analyze the recent business situations of SATSUMA PHARMACEUTICALS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average STSA stock price target is 4.500 with a high estimate of 7.00 and a low estimate of 3.500.
EPS
Institutional Holdings
Institutions: 72
Institutional Holdings: 9.80M
% Owned: 56.28%
Shares Outstanding: 17.42M
TypeInstitutionsShares
Increased
10
421.50K
New
34
-3.42M
Decreased
15
991.18K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Heath Lukatch
President/Chief Executive Officer/Director
John Kollins
Chief Financial Officer/Primary Contact
Tom O'Neil
Vice President
Mic Iwashima
Other
Detlef Albrecht
Other
Rob Janosky
Director
Thomas Soloway
Independent Director
Thomas King
Independent Director
Michael Riebe
Independent Director
Elisabeth Sandoval
Independent Director
Rajeev Shah
Independent Director
Ken Takanashi
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About STSA
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the treatment of migraine. The Company’s product candidate STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be self-administered with a proprietary pre-filled, single-use, nasal delivery device.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Satsuma Pharmaceuticals Inc stock information, including NASDAQ:STSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading STSA stock methods without spending real money on the virtual paper trading platform.